EMA Authorised: Vfend (voriconazole) — Pfizer Europe MA EEIG

View source ↗

Summary

Pfizer's voriconazole (Vfend) has been authorised by EMA for use in fungal infections including candidiasis, mycoses, and aspergillosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aspergillosis
• Candidiasis
• Mycoses

Drugs mentioned

• VFEND (Voriconazole)

Snippet

Status: Authorised. Therapeutic area: Candidiasis;Mycoses;Aspergillosis. MAH: Pfizer Europe MA EEIG. Decision date: 04/06/2026